Programmed death ligand-1 (PD-L1) expression in serous ovarian carcinoma with clinicopathological associations.

Authors

Anubhuti Chaturvedi, Reena Tomar, Shramana Mandal, Deepti Goswami, Nita Khurana

Published in

The Indian journal of medical research. Volume 164. Issue 1. Pages 98-102.

Abstract

Background and objectives The prevalence and significance of programmed death-1 ligand (PD-L1) expression in serous ovarian carcinoma are not well established. This study aimed to evaluate PD-L1 expression using immunohistochemistry (IHC) in whole tissue sections of serous ovarian carcinoma and to correlate its expression with relevant clinicopathological characteristics. Methods A retrospective study of 30 cases was conducted at a tertiary care centre in New Delhi, India, over one yr. All cases were reviewed using HandE staining, and IHC for PD-L1 was performed manually on poly-L-lysine-coated slides using the PD-L1 (E1L3N®) XP® Rabbit monoclonal antibody. Additional clinicomorphological data were recorded and analysed. Results Based on the combined positive score (CPS) with a 1% cutoff, PD-L1 expression was observed in 33% of cases. PD-L1 expression demonstrated a positive correlation with higher FIGO stage and the presence of tumour-infiltrating lymphocytes (TILs) (P=0.029). Interpretation and conclusion PD-L1 may serve as a potential prognostic marker in serous ovarian carcinoma. Its expression could help identify patients who may benefit from targeted PD-L1-based therapies and contributes to a better understanding of the biological behaviour of ovarian carcinoma.

PMID:
42397824
Bibliographic data and abstract were imported from PubMed on 04 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.